百时美施贵宝(BMY.US)CAR-T疗法递交FDA监管申请，治疗淋巴瘤_老虎社区_美港股上老虎

百时美施贵宝(BMY.US)CAR-T疗法递交FDA监管申请，治疗淋巴瘤

智通财经网2019-12-20

当地时间12月19日，百时美施贵宝(BMY.US)官网发布公告，已经向FDA递交了靶向CD19抗原的CAR-T疗法lisocabtagene maraleucel（liso-cel）的生物制品许可申请（BLA）。liso-cel旨在治疗复发/难治性（R/R）大B细胞淋巴瘤（LBCL）成人患者，包括弥漫性大B细胞淋巴瘤患者（DLBCL）。这些患者至少接受过两种前期疗法。据悉，liso-cel目前暂无...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1992037221?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","is_english":false,"pubTime":"2019-12-20 09:58","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"1992037221","market":"us","top_or_hot":-1,"title":"百时美施贵宝(BMY.US)CAR-T疗法递交FDA监管申请，治疗淋巴瘤","media":"智通财经网","content":"<div>\n<p>当地时间12月19日，百时美施贵宝(BMY.US)官网发布公告，已经向FDA递交了靶向CD19抗原的CAR-T疗法lisocabtagene maraleucel（liso-cel）的生物制品许可申请（BLA）。liso-cel旨在治疗复发/难治性（R/R）大B细胞淋巴瘤（LBCL）成人患者，包括弥漫性大B细胞淋巴瘤患者（DLBCL）。这些患者至少接受过两种前期疗法。据悉，liso-cel目前暂无...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2019-12-20/doc-iihnzhfz7121410.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百时美施贵宝(BMY.US)CAR-T疗法递交FDA监管申请，治疗淋巴瘤</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百时美施贵宝(BMY.US)CAR-T疗法递交FDA监管申请，治疗淋巴瘤\n</h2>\n\n<h4 class=\"meta\">\n\n\n2019-12-20 09:58 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2019-12-20/doc-iihnzhfz7121410.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>当地时间12月19日，百时美施贵宝(BMY.US)官网发布公告，已经向FDA递交了靶向CD19抗原的CAR-T疗法lisocabtagene maraleucel（liso-cel）的生物制品许可申请（BLA）。liso-cel旨在治疗复发/难治性（R/R）大B细胞淋巴瘤（LBCL）成人患者，包括弥漫性大B细胞淋巴瘤患者（DLBCL）。这些患者至少接受过两种前期疗法。据悉，liso-cel目前暂无...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2019-12-20/doc-iihnzhfz7121410.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2019-12-20/doc-iihnzhfz7121410.shtml","article_id":"1992037221","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1992037221","pubTimestamp":1576807080,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"当地时间12月19日，百时美施贵宝(BMY.US)官网发布公告，已经向FDA递交了靶向CD19抗原的CAR-T疗法lisocabtagene maraleucel（liso-cel）的生物制品许可申请","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Bristol-Myers Squibb (BMY.US) CAR-T Therapy Submitted FDA Regulatory Application to Treat Lymphoma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"当地时间12月19日，百时美施贵宝(BMY.US)官网发布公告，已经向FDA递交了靶向CD19抗原的CAR-T疗法lisocabtagene maraleucel（liso-cel）的生物制品许可申请（BLA）。liso-cel旨在治疗复发/难治性（R/R）大B细胞淋巴瘤（LBCL）成人患者，包括弥漫性大B细胞淋巴瘤患者（DLBCL）。这些患者至少接受过两种前期疗法。据悉，liso-cel目前暂无许可在任何国家使用，早前被FDA授予突破性疗法和再生医学高级疗法的称号，它的独特之处是CAR-T疗法中CD8阳性和CD4阳性T细胞的比例得到控制，从而可以更好地控制细胞疗法的毒副作用。该申请基于liso-cel在名为TRANSCEND NHL 001临床试验的安全性和数据，该试验评估了269例复发/难治性大B细胞淋巴瘤，包括弥漫性大B细胞淋巴瘤（DLBCL）患者的治疗数据。百时美施贵宝公司最近在美国血液学学会年会上公布了这项重要研究的数据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}